The Effects of Glucomannan on Weight Loss
Primary Purpose
Obesity
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Glucomannan
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Overweight, Glucomannan
Eligibility Criteria
Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to lose 50 pounds.
Subjects must be able to swallow the capsule whole with water.
Exclusion Criteria:
- Self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)
- Pregnancy
- Age younger than 21 or older than 60 years of age.
- Screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90.
- BMI calculations based upon height and weight measurements at the first laboratory visit that reveal a BMI less than 25 or greater than 35.
- Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Gucomannan
Placebo pill
Arm Description
Outcomes
Primary Outcome Measures
Weight Loss
Secondary Outcome Measures
Full Information
NCT ID
NCT01709955
First Posted
October 16, 2012
Last Updated
October 17, 2012
Sponsor
Northeast College of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT01709955
Brief Title
The Effects of Glucomannan on Weight Loss
Study Type
Interventional
2. Study Status
Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northeast College of Health Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if the herb, Glucomannan, is an effective non-pharmacological appetite suppressant for overweight or Class I obese patients. The study design will not include any other lifestyle changes which enhance weight loss in order to completely isolate the effects of Glucomannan as a non-pharmacological appetite suppressant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Overweight, Glucomannan
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Gucomannan
Arm Type
Experimental
Arm Title
Placebo pill
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Glucomannan
Intervention Description
750 MG of Glucomannan in capsule form
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
750 mg of Cellulose powder in a capsule form
Primary Outcome Measure Information:
Title
Weight Loss
Time Frame
30 Days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to lose 50 pounds.
Subjects must be able to swallow the capsule whole with water.
Exclusion Criteria:
Self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)
Pregnancy
Age younger than 21 or older than 60 years of age.
Screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90.
BMI calculations based upon height and weight measurements at the first laboratory visit that reveal a BMI less than 25 or greater than 35.
Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.
12. IPD Sharing Statement
Learn more about this trial
The Effects of Glucomannan on Weight Loss
We'll reach out to this number within 24 hrs